Policy & Regulation
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
16 March 2026 - Biopharmaceutical company Avacta Group plc (AIM:AVCT) reported on Monday that it has opened a Phase 1 clinical trial for FAP-Exd (AVA6103), its second pipeline programme and the first ...
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
...
LynxKite Technologies expands Biophytis collaboration
16 March 2026 - Singapore-based advanced analytics and artificial intelligence specialist LynxKite Technologies Pte Ltd announced on Friday that it is expanding its partnership with Biophytis SA (Euro...
BioDlink named 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Excellence Awards
16 March 2026 - BioDlink Biopharm Co Ltd, a China-based Contract Development and Manufacturing Organisation (CDMO), announced on Friday that it has been recognised as 'Emerging CDMO of the Year&#...
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
16 March 2026 - Vimgreen Pharmaceuticals, a Chinese developer of novel therapeutics targeting adenosine signalling pathways, with a focus on addressing unmet medical needs in neurodegenerative, metabo...
Emerald Clinical Trials honoured with 2026 Asia Pacific Biopharma Excellence Award
13 March 2026 - Emerald Clinical Trials, a global clinical research organisation (CRO), announced on Thursday that it has received the Best Clinical Trials Supplier Award: Outstanding Patient Recruitm...